Clinical case analysis——cough and hemoptysis for more than 3 months
10.3760/cma.j.cn141217-20240918-00274
- VernacularTitle:临床病例评析——咳嗽 咯血3个月余
- Author:
Ningning GONG
1
;
Jiuliang ZHAO
;
Yangzhong ZHOU
;
Mengtao LI
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院风湿免疫科，北京 100730
- Publication Type:Journal Article
- Keywords:
Antiphospholipid syndrome;
Diffuse alveolar hemorrhage;
Antiphospholipid antibodies;
Microvascular events
- From:
Chinese Journal of Rheumatology
2025;29(2):128-132
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To improve clinical understanding of diffuse alveolar hemorrhage (DAH) secondary to antiphospholipid syndrome (APS).Methods:A patient with DAH as the initial symptom and positive for antiphospholipid antibodies (aPLs) was reported, and their clinical characteristics and diagnosis and treatment process were analyzed.Results:A 43 year old male patient presented with "cough and hemoptysis for more than 3 months", and the imaging and bronchoalveolar lavage fluid confirmed DAH. During the course of the disease, there was a decrease in platelets and an increase in inflammatory markers, as well as high titers of various antiphospholipid antibodies. After excluding other potential causes, the final diagnosis was APS secondary DAH. After receiving high-dose glucocorticoid and immunosuppressant, the patient′s condition was relieved, pulmonary lesions were absorbed, platelets recovered, and aPLs titer decreased.Conclusion:For unexplained DAH, it is necessary to further exclude infection and other factors before screening autoimmune diseases. The patient was diagnosed as APS-DAH after actively screening the cause, and the lesion was absorbed after hormone and cyclophosphamide treatment.Early identification of microvascular events is crucial for improving patient prognosis.
